1. Home
  2. KALV vs KODK Comparison

KALV vs KODK Comparison

Compare KALV & KODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALV
  • KODK
  • Stock Information
  • Founded
  • KALV N/A
  • KODK 1880
  • Country
  • KALV United States
  • KODK United States
  • Employees
  • KALV N/A
  • KODK N/A
  • Industry
  • KALV Biotechnology: Pharmaceutical Preparations
  • KODK Business Services
  • Sector
  • KALV Health Care
  • KODK Consumer Discretionary
  • Exchange
  • KALV Nasdaq
  • KODK Nasdaq
  • Market Cap
  • KALV 551.2M
  • KODK 476.6M
  • IPO Year
  • KALV N/A
  • KODK N/A
  • Fundamental
  • Price
  • KALV $13.62
  • KODK $7.45
  • Analyst Decision
  • KALV Strong Buy
  • KODK
  • Analyst Count
  • KALV 8
  • KODK 0
  • Target Price
  • KALV $26.43
  • KODK N/A
  • AVG Volume (30 Days)
  • KALV 1.2M
  • KODK 1.8M
  • Earning Date
  • KALV 11-10-2025
  • KODK 11-06-2025
  • Dividend Yield
  • KALV N/A
  • KODK N/A
  • EPS Growth
  • KALV N/A
  • KODK N/A
  • EPS
  • KALV N/A
  • KODK N/A
  • Revenue
  • KALV $1,426,000.00
  • KODK $1,045,000,000.00
  • Revenue This Year
  • KALV N/A
  • KODK N/A
  • Revenue Next Year
  • KALV $234.65
  • KODK N/A
  • P/E Ratio
  • KALV N/A
  • KODK N/A
  • Revenue Growth
  • KALV N/A
  • KODK N/A
  • 52 Week Low
  • KALV $7.30
  • KODK $4.26
  • 52 Week High
  • KALV $17.28
  • KODK $8.90
  • Technical
  • Relative Strength Index (RSI)
  • KALV 70.91
  • KODK 54.72
  • Support Level
  • KALV $10.55
  • KODK $5.78
  • Resistance Level
  • KALV $13.44
  • KODK $8.90
  • Average True Range (ATR)
  • KALV 0.65
  • KODK 0.56
  • MACD
  • KALV 0.36
  • KODK 0.15
  • Stochastic Oscillator
  • KALV 94.79
  • KODK 51.20

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About KODK Eastman Kodak Company Common New

Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.

Share on Social Networks: